Back to top

RBC Capital Reaffirms Their Buy Rating on RegenXBio (RGNX)

In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on RegenXBio, with a price target of $19.00. The company’s share...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

REGENXBIO Inc. (RGNX)